We have developed a new approach to immuno onchology and are beginning animal trials. We iexpect to begin human trials in glioblastoma in early2025
Our therapeutic agent is a fusion protein between a disease targeting nanobody and an enzyme which produces oxygen free radicals in the microenvironment of the target.
Our first fusion protein is between a llama vhh which binds to EGFR and the enzyme xanthine oxidase. We have shown it works as expected in cell culture and we are currently finishing a group os in vivo studies in mice with glioblastoma and colon cancer growing in them.
Ready to Ask For Funding for your company?
Post a Funding Request